MedTrace Logo

Ultra Violet B Radiation (UVR) Study of Strontium Chloride Hexahydrate Hydrocortisone

NCT01301677 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 47

Last updated 2011-06-29

No results posted yet for this study

Summary

Double blinded (subject and observer), randomised, active (hydrocortisone (HC)) controlled study of the effect of strontium chloride hexahydrate on ultraviolet B radiation (UVR) induced signs of inflammation (erythema and pain) in healthy volunteers.

Conditions

Interventions

DRUG

Hydrocortisone

Hydrocortisone liquid formulation

DRUG

2PX+

strontium chloride hexahydrate in a penetration enhancing vehicle

DRUG

2PX-

strontium chloride hexahydrate without a penetration enhancing vehicle

Sponsors & Collaborators

  • X-pert Med GmbH

    lead INDUSTRY

Principal Investigators

  • Ilka Rother, MD · X-pert Med GmbH

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-01-31
Primary Completion
2011-06-30
Completion
2011-06-30

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01301677 on ClinicalTrials.gov